Effects of new hypoglycemic drugs on patients with heart failure: a systematic review and network meta-analysis.

Song R, Liu F, Shi X, Sun S, Chen J, Gao H

Postgraduate medical journal1 Mar 2025Cited by 1 (Europe PMC)

PMID39487697DOI10.1093/postmj/qgae148PepBankPUB-39487697

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

3 results from studies that gave the peptide. 3 results from people.

01HumanSystematic reviewEfficacy outcome
In reviewed heart-failure patients, rehospitalization differed for dapagliflozin 10 mg versus liraglutide 1.8 mg (printed MD 0.45, 95% CI 0.25 to 0.82; metric interpretation unspecified).
In plain wordsIn reviewed heart-failure patients, rehospitalization differed between dapagliflozin and liraglutide; the reported metric was unclear.
Peptide
Liraglutide
Outcome
Direction not reportedHeart failure rehospitalization
Study
n: not reported in source
Comparator
Dapagliflozin 10 mg
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
1.8 mgAs given in this study (human).
Measurements
Reported effect estimate (source labels MD)
0.45
dapagliflozin 10 mg versus liraglutide 1.8 mg; 95% CI 0.25 to 0.82; interpretation/unit unspecified
Source sentences
Summary
In terms of the cardiovascular outcome events, there is a significant difference in the heart failure rehospitalization rate of Dapagliflozin 10 mg (0.45; 0.25, 0.82) and Empagliflozin 10 mg (0.48; 0.28, 0.81) compared to Liraglutide 1.8 mg.
4 context sentences(design, population, supporting numbers)
Summary · context
We conducted a comprehensive literature search across multiple databases.
Summary · context
Utilizing the risk of bias tool from the Cochrane Collaboration, the methodological quality of included studies was critically assessed and potential publication bias was examined via funnel plots.
Summary · context
All results are presented as mean difference; 95% confidence interval (MD; 95% CI).
Title · context
Effects of new hypoglycemic drugs on patients with heart failure: a systematic review and network meta-analysis.
Report a problemFND-3948769701
02HumanSystematic reviewEfficacy outcome
In reviewed heart-failure patients, arrhythmic events differed for liraglutide 1.8 mg versus empagliflozin 10 mg (printed MD 0.49, 95% CI 0.26 to 0.90; metric interpretation unspecified).
In plain wordsIn reviewed heart-failure patients, arrhythmic events differed between liraglutide and empagliflozin; the reported metric was unclear.
Peptide
Liraglutide
Outcome
Direction not reportedArrhythmic events
Study
n: not reported in source
Comparator
Empagliflozin 10 mg
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
1.8 mgAs given in this study (human).
Measurements
Reported effect estimate (source labels MD)
0.49
liraglutide 1.8 mg versus empagliflozin 10 mg; 95% CI 0.26 to 0.90; interpretation/unit unspecified
Source sentences
Summary
and the arrhythmic events of Liraglutide 1.8 mg (0.49; 0.26, 0.90) compared to Empagliflozin 10 mg.
4 context sentences(design, population, supporting numbers)
Summary · context
We conducted a comprehensive literature search across multiple databases.
Summary · context
Utilizing the risk of bias tool from the Cochrane Collaboration, the methodological quality of included studies was critically assessed and potential publication bias was examined via funnel plots.
Summary · context
All results are presented as mean difference; 95% confidence interval (MD; 95% CI).
Title · context
Effects of new hypoglycemic drugs on patients with heart failure: a systematic review and network meta-analysis.
Report a problemFND-3948769702
03HumanSystematic reviewEfficacy outcome
In reviewed heart-failure patients, rehospitalization differed for empagliflozin 10 mg versus liraglutide 1.8 mg (printed MD 0.48, 95% CI 0.28 to 0.81; metric interpretation unspecified).
In plain wordsIn reviewed heart-failure patients, rehospitalization differed between empagliflozin and liraglutide; the reported metric was unclear.
Peptide
Liraglutide
Outcome
Direction not reportedHeart failure rehospitalization
Study
n: not reported in source
Comparator
Empagliflozin 10 mg
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
1.8 mgAs given in this study (human).
Measurements
Reported effect estimate (source labels MD)
0.48
empagliflozin 10 mg versus liraglutide 1.8 mg; 95% CI 0.28 to 0.81; interpretation/unit unspecified
Source sentences
Summary
In terms of the cardiovascular outcome events, there is a significant difference in the heart failure rehospitalization rate of Dapagliflozin 10 mg (0.45; 0.25, 0.82) and Empagliflozin 10 mg (0.48; 0.28, 0.81) compared to Liraglutide 1.8 mg.
4 context sentences(design, population, supporting numbers)
Summary · context
We conducted a comprehensive literature search across multiple databases.
Summary · context
Utilizing the risk of bias tool from the Cochrane Collaboration, the methodological quality of included studies was critically assessed and potential publication bias was examined via funnel plots.
Summary · context
All results are presented as mean difference; 95% confidence interval (MD; 95% CI).
Title · context
Effects of new hypoglycemic drugs on patients with heart failure: a systematic review and network meta-analysis.
Report a problemFND-3948769705

Studies that did not test the peptide alone2

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

04HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In reviewed heart-failure patients, pooled GLP-1 receptor agonists were superior to SGLT2 inhibitors in improving LVEF; the signed coefficient was unstated.
In plain wordsIn reviewed heart-failure patients, pooled GLP-1 drugs improved heart pumping more than SGLT2 inhibitors; the signed estimate was unstated.
Peptide
Liraglutide
Outcome
Direction not reportedLeft ventricular ejection fraction
Study
n: not reported in source
Comparator
SGLT2 inhibitors
Outcome group
Heart function · Cardiovascular
Source sentences
Summary
The network meta-analysis of SGLT2i, GLP-1RA, and DPP4i as a class of drugs showed that GLP-1RA is superior to SGLT2i in improving LVEF and reducing myocardial infarction/acute coronary syndrome, whereas DPP4i is superior to SGLT2i in improving LVEDV and LVESV.
4 context sentences(design, population, supporting numbers)
Summary · context
We conducted a comprehensive literature search across multiple databases.
Summary · context
Utilizing the risk of bias tool from the Cochrane Collaboration, the methodological quality of included studies was critically assessed and potential publication bias was examined via funnel plots.
Summary · context
All results are presented as mean difference; 95% confidence interval (MD; 95% CI).
Title · context
Effects of new hypoglycemic drugs on patients with heart failure: a systematic review and network meta-analysis.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3948769703
05HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In reviewed heart-failure patients, pooled GLP-1 receptor agonists reduced myocardial infarction/acute coronary syndrome more than SGLT2 inhibitors.
In plain wordsIn reviewed heart-failure patients, pooled GLP-1 drugs reduced heart attack/acute coronary syndrome more than SGLT2 inhibitors.
Peptide
Liraglutide
Outcome
DecreaseMyocardial infarction or acute coronary syndrome
Study
n: not reported in source
Comparator
SGLT2 inhibitors
Outcome group
Cardiovascular events · Cardiovascular
Source sentences
Summary
The network meta-analysis of SGLT2i, GLP-1RA, and DPP4i as a class of drugs showed that GLP-1RA is superior to SGLT2i in improving LVEF and reducing myocardial infarction/acute coronary syndrome, whereas DPP4i is superior to SGLT2i in improving LVEDV and LVESV.
4 context sentences(design, population, supporting numbers)
Summary · context
We conducted a comprehensive literature search across multiple databases.
Summary · context
Utilizing the risk of bias tool from the Cochrane Collaboration, the methodological quality of included studies was critically assessed and potential publication bias was examined via funnel plots.
Summary · context
All results are presented as mean difference; 95% confidence interval (MD; 95% CI).
Title · context
Effects of new hypoglycemic drugs on patients with heart failure: a systematic review and network meta-analysis.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3948769704

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.